stockportfolio.pro
Beam Therapeutics Inc. (BEAM)
Healthcare · Biotechnology · NasdaqGS
Beam Therapeutics Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $18,000 | $24,000 | $51.84M | $60.92M | $377.71M | $63.52M | $139.74M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-78.33M | $-194.59M | $-370.64M | $-289.09M | $-132.53M | $-376.74M | $-79.99M |
| Net margin | -435144.4% | -810800.0% | -714.9% | -474.5% | -35.1% | -593.1% | -57.2% |
Source: Beam Therapeutics Inc. SEC filings (10-K).
Explore 7 years of Beam Therapeutics Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BEAM in your portfolio →
Beam Therapeutics Inc. financial history by metric
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Beam Therapeutics Inc. — frequently asked questions
What is Beam Therapeutics Inc.'s revenue?
Beam Therapeutics Inc. (BEAM) reported revenue of $139.74M for fiscal year 2025, up 120.0% from the prior year, according to its SEC filings.
Is Beam Therapeutics Inc. profitable?
No — BEAM reported a net loss of $-79.99M in fiscal 2025.
What is BEAM's P/E ratio?
Beam Therapeutics Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Beam Therapeutics Inc. growing?
BEAM's revenue grew at roughly 466.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Beam Therapeutics Inc. have?
As of fiscal year 2025, BEAM carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Beam Therapeutics Inc.'s market cap?
Beam Therapeutics Inc. (BEAM) has a market capitalization of about $3.02B, based on the latest data in our nightly-refreshed cache.
When does Beam Therapeutics Inc.'s fiscal year end?
BEAM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Beam Therapeutics Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.